Validation of a Human Papillomavirus (HPV) DNA cervical screening test that provides expanded HPV typing

Maria Demarco, Olivia Carter-Pokras, Noorie Hyun, Philip E. Castle, Xin He, Cher M. Dallal, Jie Chen, Julia C. Gage, Brian Befano, Barbara Fetterman, Thomas Lorey, Nancy Poitras, Tina R. Raine-Bennett, Nicolas Wentzensen, Mark Schiffman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

As cervical cancer screening shifts from cytology to human papillomavirus (HPV) testing, a major question is the clinical value of identifying individual HPV types. We aimed to validate Onclarity (Becton Dickinson Diagnostics, Sparks, MD), a nine-channel HPV test recently approved by the FDA, by assessing (i) the association of Onclarity types/channels with precancer/cancer; (ii) HPV type/channel agreement between the results of Onclarity and cobas (Roche Molecular Systems, Pleasanton, CA), another FDA-approved test; and (iii) Onclarity typing for all types/channels compared to typing results from a research assay (linear array [LA]; Roche). We compared Onclarity to histopathology, cobas, and LA. We tested a stratified random sample (n 9,701) of discarded routine clinical specimens that had tested positive by Hybrid Capture 2 (HC2; Qiagen, Germantown, MD). A subset had already been tested by cobas and LA (n 1,965). Cervical histopathology was ascertained from electronic health records. Hierarchical Onclarity channels showed a significant linear association with histological severity. Onclarity and cobas had excellent agreement on partial typing of HPV16, HPV18, and the other 12 types as a pool (sample-weighted kappa value of 0.83); cobas was slightly more sensitive for HPV18 and slightly less sensitive for the pooled high-risk types. Typing by Onclarity showed excellent agreement with types and groups of types identified by LA (kappa values from 0.80 for HPV39/68/35 to 0.97 for HPV16). Onclarity typing results corresponded well to histopathology and to an already validated HPV DNA test and could provide additional clinical typing if such discrimination is determined to be clinically desirable.

Original languageEnglish (US)
Article numbere01910-17
JournalJournal of Clinical Microbiology
Volume56
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

DNA
Human Papillomavirus DNA Tests
Electronic Health Records
Early Detection of Cancer
Uterine Cervical Neoplasms
Cell Biology
Research
Neoplasms

Keywords

  • Cervical screening
  • Cobas
  • Genotyping
  • HPV DNA test
  • Onclarity
  • Typing

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Validation of a Human Papillomavirus (HPV) DNA cervical screening test that provides expanded HPV typing. / Demarco, Maria; Carter-Pokras, Olivia; Hyun, Noorie; Castle, Philip E.; He, Xin; Dallal, Cher M.; Chen, Jie; Gage, Julia C.; Befano, Brian; Fetterman, Barbara; Lorey, Thomas; Poitras, Nancy; Raine-Bennett, Tina R.; Wentzensen, Nicolas; Schiffman, Mark.

In: Journal of Clinical Microbiology, Vol. 56, No. 5, e01910-17, 01.05.2018.

Research output: Contribution to journalArticle

Demarco, M, Carter-Pokras, O, Hyun, N, Castle, PE, He, X, Dallal, CM, Chen, J, Gage, JC, Befano, B, Fetterman, B, Lorey, T, Poitras, N, Raine-Bennett, TR, Wentzensen, N & Schiffman, M 2018, 'Validation of a Human Papillomavirus (HPV) DNA cervical screening test that provides expanded HPV typing', Journal of Clinical Microbiology, vol. 56, no. 5, e01910-17. https://doi.org/10.1128/JCM.01910-17
Demarco, Maria ; Carter-Pokras, Olivia ; Hyun, Noorie ; Castle, Philip E. ; He, Xin ; Dallal, Cher M. ; Chen, Jie ; Gage, Julia C. ; Befano, Brian ; Fetterman, Barbara ; Lorey, Thomas ; Poitras, Nancy ; Raine-Bennett, Tina R. ; Wentzensen, Nicolas ; Schiffman, Mark. / Validation of a Human Papillomavirus (HPV) DNA cervical screening test that provides expanded HPV typing. In: Journal of Clinical Microbiology. 2018 ; Vol. 56, No. 5.
@article{65a5a471d1434bf7abc96fe08794d80d,
title = "Validation of a Human Papillomavirus (HPV) DNA cervical screening test that provides expanded HPV typing",
abstract = "As cervical cancer screening shifts from cytology to human papillomavirus (HPV) testing, a major question is the clinical value of identifying individual HPV types. We aimed to validate Onclarity (Becton Dickinson Diagnostics, Sparks, MD), a nine-channel HPV test recently approved by the FDA, by assessing (i) the association of Onclarity types/channels with precancer/cancer; (ii) HPV type/channel agreement between the results of Onclarity and cobas (Roche Molecular Systems, Pleasanton, CA), another FDA-approved test; and (iii) Onclarity typing for all types/channels compared to typing results from a research assay (linear array [LA]; Roche). We compared Onclarity to histopathology, cobas, and LA. We tested a stratified random sample (n 9,701) of discarded routine clinical specimens that had tested positive by Hybrid Capture 2 (HC2; Qiagen, Germantown, MD). A subset had already been tested by cobas and LA (n 1,965). Cervical histopathology was ascertained from electronic health records. Hierarchical Onclarity channels showed a significant linear association with histological severity. Onclarity and cobas had excellent agreement on partial typing of HPV16, HPV18, and the other 12 types as a pool (sample-weighted kappa value of 0.83); cobas was slightly more sensitive for HPV18 and slightly less sensitive for the pooled high-risk types. Typing by Onclarity showed excellent agreement with types and groups of types identified by LA (kappa values from 0.80 for HPV39/68/35 to 0.97 for HPV16). Onclarity typing results corresponded well to histopathology and to an already validated HPV DNA test and could provide additional clinical typing if such discrimination is determined to be clinically desirable.",
keywords = "Cervical screening, Cobas, Genotyping, HPV DNA test, Onclarity, Typing",
author = "Maria Demarco and Olivia Carter-Pokras and Noorie Hyun and Castle, {Philip E.} and Xin He and Dallal, {Cher M.} and Jie Chen and Gage, {Julia C.} and Brian Befano and Barbara Fetterman and Thomas Lorey and Nancy Poitras and Raine-Bennett, {Tina R.} and Nicolas Wentzensen and Mark Schiffman",
year = "2018",
month = "5",
day = "1",
doi = "10.1128/JCM.01910-17",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Validation of a Human Papillomavirus (HPV) DNA cervical screening test that provides expanded HPV typing

AU - Demarco, Maria

AU - Carter-Pokras, Olivia

AU - Hyun, Noorie

AU - Castle, Philip E.

AU - He, Xin

AU - Dallal, Cher M.

AU - Chen, Jie

AU - Gage, Julia C.

AU - Befano, Brian

AU - Fetterman, Barbara

AU - Lorey, Thomas

AU - Poitras, Nancy

AU - Raine-Bennett, Tina R.

AU - Wentzensen, Nicolas

AU - Schiffman, Mark

PY - 2018/5/1

Y1 - 2018/5/1

N2 - As cervical cancer screening shifts from cytology to human papillomavirus (HPV) testing, a major question is the clinical value of identifying individual HPV types. We aimed to validate Onclarity (Becton Dickinson Diagnostics, Sparks, MD), a nine-channel HPV test recently approved by the FDA, by assessing (i) the association of Onclarity types/channels with precancer/cancer; (ii) HPV type/channel agreement between the results of Onclarity and cobas (Roche Molecular Systems, Pleasanton, CA), another FDA-approved test; and (iii) Onclarity typing for all types/channels compared to typing results from a research assay (linear array [LA]; Roche). We compared Onclarity to histopathology, cobas, and LA. We tested a stratified random sample (n 9,701) of discarded routine clinical specimens that had tested positive by Hybrid Capture 2 (HC2; Qiagen, Germantown, MD). A subset had already been tested by cobas and LA (n 1,965). Cervical histopathology was ascertained from electronic health records. Hierarchical Onclarity channels showed a significant linear association with histological severity. Onclarity and cobas had excellent agreement on partial typing of HPV16, HPV18, and the other 12 types as a pool (sample-weighted kappa value of 0.83); cobas was slightly more sensitive for HPV18 and slightly less sensitive for the pooled high-risk types. Typing by Onclarity showed excellent agreement with types and groups of types identified by LA (kappa values from 0.80 for HPV39/68/35 to 0.97 for HPV16). Onclarity typing results corresponded well to histopathology and to an already validated HPV DNA test and could provide additional clinical typing if such discrimination is determined to be clinically desirable.

AB - As cervical cancer screening shifts from cytology to human papillomavirus (HPV) testing, a major question is the clinical value of identifying individual HPV types. We aimed to validate Onclarity (Becton Dickinson Diagnostics, Sparks, MD), a nine-channel HPV test recently approved by the FDA, by assessing (i) the association of Onclarity types/channels with precancer/cancer; (ii) HPV type/channel agreement between the results of Onclarity and cobas (Roche Molecular Systems, Pleasanton, CA), another FDA-approved test; and (iii) Onclarity typing for all types/channels compared to typing results from a research assay (linear array [LA]; Roche). We compared Onclarity to histopathology, cobas, and LA. We tested a stratified random sample (n 9,701) of discarded routine clinical specimens that had tested positive by Hybrid Capture 2 (HC2; Qiagen, Germantown, MD). A subset had already been tested by cobas and LA (n 1,965). Cervical histopathology was ascertained from electronic health records. Hierarchical Onclarity channels showed a significant linear association with histological severity. Onclarity and cobas had excellent agreement on partial typing of HPV16, HPV18, and the other 12 types as a pool (sample-weighted kappa value of 0.83); cobas was slightly more sensitive for HPV18 and slightly less sensitive for the pooled high-risk types. Typing by Onclarity showed excellent agreement with types and groups of types identified by LA (kappa values from 0.80 for HPV39/68/35 to 0.97 for HPV16). Onclarity typing results corresponded well to histopathology and to an already validated HPV DNA test and could provide additional clinical typing if such discrimination is determined to be clinically desirable.

KW - Cervical screening

KW - Cobas

KW - Genotyping

KW - HPV DNA test

KW - Onclarity

KW - Typing

UR - http://www.scopus.com/inward/record.url?scp=85046303465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046303465&partnerID=8YFLogxK

U2 - 10.1128/JCM.01910-17

DO - 10.1128/JCM.01910-17

M3 - Article

C2 - 29491018

AN - SCOPUS:85046303465

VL - 56

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 5

M1 - e01910-17

ER -